BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 8885849)

  • 1. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives.
    Ratmeyer L; Zapp ML; Green MR; Vinayak R; Kumar A; Boykin DW; Wilson WD
    Biochemistry; 1996 Oct; 35(42):13689-96. PubMed ID: 8885849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors.
    Luedtke NW; Tor Y
    Biopolymers; 2003 Sep; 70(1):103-19. PubMed ID: 12925996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine side-chain dynamics in the HIV-1 rev-RRE complex.
    Wilkinson TA; Botuyan MV; Kaplan BE; Rossi JJ; Chen Y
    J Mol Biol; 2000 Nov; 303(4):515-29. PubMed ID: 11054288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element.
    Luedtke NW; Liu Q; Tor Y
    Biochemistry; 2003 Oct; 42(39):11391-403. PubMed ID: 14516190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of HIV Rev peptides with the Rev response element RNA.
    Williamson JR; Battiste JL; Mao H; Frankel AD
    Nucleic Acids Symp Ser; 1995; (33):46-8. PubMed ID: 8643394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA.
    Daly TJ; Doten RC; Rusche JR; Auer M
    J Mol Biol; 1995 Oct; 253(2):243-58. PubMed ID: 7563086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dynamic in vivo view of the HIV-I Rev-RRE interaction.
    Charpentier B; Stutz F; Rosbash M
    J Mol Biol; 1997 Mar; 266(5):950-62. PubMed ID: 9086273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-triggered conformational switch in HIV-1 RRE RNA complexes.
    Gosser Y; Hermann T; Majumdar A; Hu W; Frederick R; Jiang F; Xu W; Patel DJ
    Nat Struct Biol; 2001 Feb; 8(2):146-50. PubMed ID: 11175904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds.
    Zapp ML; Young DW; Kumar A; Singh R; Boykin DW; Wilson WD; Green MR
    Bioorg Med Chem; 1997 Jun; 5(6):1149-55. PubMed ID: 9222509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A heterocyclic inhibitor of the REV-RRE complex binds to RRE as a dimer.
    Li K; Davis TM; Bailly C; Kumar A; Boykin DW; Wilson WD
    Biochemistry; 2001 Feb; 40(5):1150-8. PubMed ID: 11170440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations.
    Xiao G; Kumar A; Li K; Rigl CT; Bajic M; Davis TM; Boykin DW; Wilson WD
    Bioorg Med Chem; 2001 May; 9(5):1097-113. PubMed ID: 11377168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.
    Nam YS; Petrovic A; Jeong KS; Venkatesan S
    J Virol; 2001 Mar; 75(6):2957-71. PubMed ID: 11222721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural change in Rev responsive element RNA of HIV-1 on binding Rev peptide.
    Peterson RD; Feigon J
    J Mol Biol; 1996 Dec; 264(5):863-77. PubMed ID: 9000617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and analysis of RNA structure-specific agents as potential antivirals.
    Wilson WD; Ratmeyer L; Zhao M; Ding D; McConnaughie AW; Kumar A; Boykin DW
    J Mol Recognit; 1996; 9(2):187-96. PubMed ID: 8877812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural RNA mimetics: N3'-->P5' phosphoramidate DNA analogs of HIV-1 RRE and TAR RNA form A-type helices that bind specifically to Rev and Tat-related peptides.
    Rigl CT; Lloyd DH; Tsou DS; Gryaznov SM; Wilson WD
    Biochemistry; 1997 Jan; 36(3):650-9. PubMed ID: 9012680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence specificity in the higher-order interaction of the Rev protein of HIV-1 with its target sequence, the RRE.
    Powell DM; Zhang MJ; Konings DA; Wingfield PT; Stahl SJ; Dayton ET; Dayton AI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):317-23. PubMed ID: 7552493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
    DeJong ES; Chang CE; Gilson MK; Marino JP
    Biochemistry; 2003 Jul; 42(26):8035-46. PubMed ID: 12834355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region.
    Wang Y; Hamasaki K; Rando RR
    Biochemistry; 1997 Jan; 36(4):768-79. PubMed ID: 9020774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear Factor 90, a cellular dsRNA binding protein inhibits the HIV Rev-export function.
    Urcuqui-Inchima S; CastaƱo ME; Hernandez-Verdun D; St-Laurent G; Kumar A
    Retrovirology; 2006 Nov; 3():83. PubMed ID: 17125513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA.
    Sugaya M; Nishino N; Katoh A; Harada K
    J Pept Sci; 2008 Aug; 14(8):924-35. PubMed ID: 18351707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.